Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. (Q40622574)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

review article

1 reference

title

Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

author name string

H J Guchelaar

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

C H ten Napel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

N H Mulder

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

publication date

1 January 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

page(s)

40-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

From yew to us: the curious development of taxol

28 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Government Moves To Increase Taxol Supply

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Investigators seek to increase taxol supply

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Surprise! A fungus factory for taxol?

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Taxol: a novel investigational antimicrotubule agent

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Mechanism of action of taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Direct photoaffinity labeling of tubulin with taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Taxol: mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Taxol sensitizes human ovarian cancer cells to radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

A phase I trial of taxol given by a 6-hour intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Chemists vie to make a better taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

The chemistry of taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Relationships between the structure of taxol analogs and their antimitotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

In vitro and in vivo antitumoral activity of free, and encapsulated taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Hypersensitivity reactions from taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Successful re-treatment with taxol after major hypersensitivity reactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Phase I study of taxol using a 5-day intermittent schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

A phase II trial of taxol in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

A phase II study of taxol in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Taxol administered as a 120 hour infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Taxol produces a predominantly sensory neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Antihistamines in the treatment of taxol-induced paroxystic pain syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Cardiac disturbances during the administration of taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Taxol and radiation recall dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Cisplatin neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Phase II Trial of Taxol in Patients with Metastatic Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

Taxol in advanced non-small-cell lung cancer: plus Ca change?

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980367-X

7 January 2021

10.1016/S0936-6555(05)80367-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7909688%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference